U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H17NO5
Molecular Weight 339.342
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOFEZOLAC

SMILES

COC1=CC=C(C=C1)C2=NOC(CC(O)=O)=C2C3=CC=C(OC)C=C3

InChI

InChIKey=DJEIHHYCDCTAAH-UHFFFAOYSA-N
InChI=1S/C19H17NO5/c1-23-14-7-3-12(4-8-14)18-16(11-17(21)22)25-20-19(18)13-5-9-15(24-2)10-6-13/h3-10H,11H2,1-2H3,(H,21,22)

HIDE SMILES / InChI

Molecular Formula C19H17NO5
Molecular Weight 339.342
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including

Mofezolac is an NSAID ) (non-steroidal anti-inflammatory drug), which acts via the cyclooxygenase enzyme, preferentially to COX-1. It also has potent inhibitory activity on the algesic responses induced by the mechanical stimulus of the inflamed tissue. It was introduced for the treatment of postoperative and posttraumatic pain, acute upper respiratory tract pain, osteoarthritis, and lumbago. It marketed only in Japan by Yoshitomi Pharmaceutical Ltd. Japan, was approved in July 1994.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Disopain

Approved Use

used to relieve inflammation/pain of lower back, cervicobrachial syndrome and scapulohumeral periarthritis. It is also used to relieve inflammation/pain after operation, trauma or tooth extraction.

Launch Date

1994
Primary
Disopain

Approved Use

used to relieve inflammation/pain of lower back, cervicobrachial syndrome and scapulohumeral periarthritis. It is also used to relieve inflammation/pain after operation, trauma or tooth extraction.

Launch Date

1994
PubMed

PubMed

TitleDatePubMed
Participation of cyclooxygenases in cutaneous thermal nociception under non-inflamed and inflamed conditions.
2001 May
Cyclooxygenase-2 inhibitors attenuate increased blood pressure in renovascular hypertensive models, but not in deoxycorticosterone-salt hypertension.
2002 Nov
Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis.
2002 Sep
Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac.
2006 Oct
Role of interleukin-1beta and tumor necrosis factor-alpha-dependent expression of cyclooxygenase-2 mRNA in thermal hyperalgesia induced by chronic inflammation in mice.
2008 Mar 18
The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro.
2009
Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework.
2010 Jun 15
Patents

Sample Use Guides

General dosage regimen (for adults): Take 1 tablet (75mg of the active ingredient) at a time three times a day after meals.
Route of Administration: Oral
In Vitro Use Guide
Mofezolac affected neither the number of TRAP-positive multinucleated cells nor the extent of lacunar resorption pits.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:26:01 GMT 2023
Edited
by admin
on Sat Dec 16 16:26:01 GMT 2023
Record UNII
RVJ0BV3H3Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOFEZOLAC
INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
MOFEZOLAC [MI]
Common Name English
MOFEZOLAC [JAN]
Common Name English
3,4-BIS(P-METHOXYPHENYL)-5-ISOXAZOLEACETIC ACID
Common Name English
MOFEZOLAC [MART.]
Common Name English
mofezolac [INN]
Common Name English
Mofezolac [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C257
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
Code System Code Type Description
RXCUI
11469
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY RxNorm
MESH
C054999
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
SMS_ID
100000080373
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
DRUG CENTRAL
1829
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
WIKIPEDIA
MOFEZOLAC
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
NCI_THESAURUS
C66176
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
FDA UNII
RVJ0BV3H3Y
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
EPA CompTox
DTXSID1046716
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
EVMPD
SUB09035MIG
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
CAS
78967-07-4
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
INN
6701
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
ChEMBL
CHEMBL259972
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
MERCK INDEX
m7588
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY Merck Index
PUBCHEM
4237
Created by admin on Sat Dec 16 16:26:01 GMT 2023 , Edited by admin on Sat Dec 16 16:26:01 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY